Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Community First Bancshares, Inc. (NASDAQ: CFBI).

Full DD Report for CFBI

You must become a subscriber to view this report.


Recent News from (NASDAQ: CFBI)

Can-Fite's Piclidenoson Mechanism of Action in Psoriasis Published in 'Journal of Immunology Research'
Phase III Psoriasis Study Scheduled for Initiation During this Quarter Psoriasis Therapeutic Market is Estimated to Reach $11.4B in 2020 Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs t...
Source: Business Wire
Date: April, 25 2018 07:00
Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL)
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today announced its poster presentation of the anti-inflammatory and anti-fibrogenic eff...
Source: Business Wire
Date: April, 09 2018 07:00
Can-Fite to Present at the MicroCap Conference
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today that it will be presenting at the MicroCap Conference, being held on Apr...
Source: Business Wire
Date: March, 28 2018 07:00
Can-Fite Reports 2017 Financial Results & Provides Clinical Update
A multi-million dollar agreement has been signed with Gebro Holdings for the distribution of Piclidenoson in 3 European Countries Phase III ACRobat trial of Piclidenoson in the treatment of rheumatoid arthritis currently enrolling patients Top-line data of Phase II with Namode...
Source: Business Wire
Date: March, 23 2018 07:00
Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today announced that Dr. Pnina Fishman, Can-Fite’s Chief Executive Officer, will ...
Source: Business Wire
Date: March, 14 2018 07:00
Can-Fite BioPharma Announces $5 Million Registered Direct Offering
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI) , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has entered into definitive agreements with institutional investors to rece...
Source: Business Wire
Date: March, 09 2018 09:00
Can-Fite to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30th Annual ROTH Conference
Renowned Key Opinion Leaders will participate in the NASH panel discussions Yet no FDA approved drug for a market estimated to reach $35-40 billion by 2025 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary sm...
Source: Business Wire
Date: March, 06 2018 07:00
Can-Fite to Present at the Inaugural LD Micro Virtual Conference
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today that it will be presenting at the inaugural LD Micro Virtual Conference ...
Source: Business Wire
Date: March, 05 2018 07:00
Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson
Accumulated safety data to date indicates potential favorable drug safety profile without hepatotoxicity Company anticipates data release to occur in H12019 Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprieta...
Source: Business Wire
Date: February, 28 2018 09:25
Can Fite Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile
The findings allow the continuation of the ongoing Phase II and Phase III clinical studies The differential effect of the drugs on pathological and normal cells accounts for the favorable safety profile Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechno...
Source: Business Wire
Date: February, 22 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1711.2511.2611.2711.15016,204

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2040064761.8238Short
2018-08-1610011090.9091Short
2018-08-14100100100.0000Short
2018-08-1330040075.0000Short
2018-08-083232100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CFBI.


About Community First Bancshares, Inc. (NASDAQ: CFBI)

Logo for Community First Bancshares, Inc. (NASDAQ: CFBI)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CFBI)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 27 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: February, 12 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: January, 23 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: December, 26 2017
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: November, 02 2017
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 11 2017
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 31 2017
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 15 2017

       

       


      Daily Technical Chart for (NASDAQ: CFBI)

      Daily Technical Chart for (NASDAQ: CFBI)


      Stay tuned for daily updates and more on (NASDAQ: CFBI)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CFBI)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CFBI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CFBI and does not buy, sell, or trade any shares of CFBI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/